HALOZYME THERAPEUTICS, INC. (HALO) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 208.97M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 1.94B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 2.58B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $208.97M | $1.94B | (m) | (m) | $2.58B | (m) |
| 2026-03-31 | (m) | (m) | $208.74M | $1.94B | (m) | (m) | $2.67B | (m) |
| 2025-12-31 | (m) | (m) | $0.00 | $2.14B | (m) | (m) | $2.53B | (m) |
| 2025-09-30 | (m) | (m) | $710.68M | $800.07M | (m) | (m) | $2.22B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $1.51B | (m) | (m) | $2.05B | (m) |
| 2025-03-31 | (m) | (m) | (m) | $1.51B | (m) | (m) | $2.20B | (m) |
| 2024-12-31 | (m) | (m) | $0.00 | $1.51B | (m) | (m) | $2.06B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $1.50B | (m) | (m) | $2.12B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $1.50B | (m) | (m) | $1.97B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $1.50B | (m) | (m) | $1.84B | (m) |
| 2023-12-31 | (m) | (m) | $0.00 | $1.50B | (m) | (m) | $1.73B | (m) |
| 2023-09-30 | (m) | (m) | $0.00 | $1.50B | (m) | (m) | $1.89B | (m) |
| 2023-06-30 | (m) | (m) | $0.00 | $1.50B | (m) | (m) | $1.81B | (m) |
| 2023-03-31 | (m) | (m) | $0.00 | $1.49B | (m) | $275.61M | $1.70B | (m) |
| 2022-12-31 | (m) | (m) | $13.33M | $1.49B | (m) | $362.79M | $1.84B | (m) |
| 2022-09-30 | (m) | (m) | $13.31M | $1.49B | (m) | $265.58M | $1.86B | (m) |
| 2022-06-30 | (m) | (m) | $99.05M | (m) | (m) | $209.36M | $1.78B | (m) |
| 2022-03-31 | (m) | (m) | $89.55M | (m) | (m) | $786.14M | $1.16B | (m) |
| 2021-12-31 | (m) | (m) | $89.42M | $787.25M | (m) | $740.92M | $1.10B | (m) |
| 2021-09-30 | (m) | (m) | $89.25M | (m) | (m) | $815.92M | $1.19B | (m) |
| 2021-06-30 | (m) | (m) | $89.17M | (m) | (m) | $755.31M | $1.03B | (m) |
| 2021-03-31 | (m) | (m) | $89.04M | (m) | (m) | $764.31M | $966.58M | (m) |
| 2020-12-31 | (m) | (m) | $397.23M | $0.00 | (m) | $368.01M | $579.92M | (m) |
| 2020-09-30 | (m) | (m) | $0.00 | (m) | (m) | $346.71M | $524.03M | (m) |
| 2020-06-30 | (m) | (m) | $0.00 | (m) | (m) | $385.45M | $527.00M | (m) |
| 2020-03-31 | (m) | (m) | $2.86M | (m) | (m) | $368.18M | $492.35M | (m) |
| 2019-12-31 | (m) | (m) | $19.54M | $383.05M | (m) | $421.26M | $565.87M | (m) |
| 2019-09-30 | (m) | (m) | $54.54M | (m) | (m) | $238.00M | $370.36M | (m) |
| 2019-06-30 | (m) | (m) | $70.88M | (m) | (m) | $287.46M | $417.83M | (m) |
| 2019-03-31 | (m) | (m) | $86.66M | (m) | (m) | $328.72M | $429.11M | (m) |
| 2018-12-31 | (m) | (m) | $91.51M | $34.87M | (m) | $354.53M | $440.25M | (m) |
| 2018-09-30 | (m) | (m) | $88.52M | (m) | (m) | $364.37M | $444.51M | (m) |
| 2018-06-30 | (m) | (m) | $86.97M | (m) | (m) | $398.89M | $474.75M | (m) |
| 2018-03-31 | (m) | (m) | $82.46M | (m) | (m) | $433.69M | $495.47M | (m) |
| 2017-12-31 | (m) | (m) | $77.21M | $125.14M | (m) | $469.21M | $519.95M | (m) |
| 2017-09-30 | (m) | (m) | $61.43M | (m) | (m) | $316.92M | $357.15M | (m) |
| 2017-06-30 | (m) | (m) | $45.52M | (m) | (m) | $297.53M | $344.79M | (m) |
| 2017-03-31 | (m) | (m) | $29.60M | (m) | (m) | $178.99M | $226.77M | (m) |
| 2016-12-31 | (m) | (m) | $17.39M | $199.23M | (m) | $204.98M | $261.51M | (m) |
| 2016-09-30 | (m) | (m) | $12.39M | (m) | (m) | $221.05M | $282.50M | (m) |
| 2016-06-30 | (m) | (m) | $3.29M | (m) | (m) | $229.99M | $296.13M | (m) |
| 2016-03-31 | (m) | (m) | $27.42M | (m) | (m) | $238.64M | $309.10M | (m) |
| 2015-12-31 | (m) | (m) | $21.86M | $27.97M | (m) | $108.34M | $181.79M | (m) |
| 2015-09-30 | (m) | (m) | $15.70M | (m) | (m) | $123.72M | $158.73M | (m) |
| 2015-06-30 | (m) | (m) | $9.66M | (m) | (m) | $140.72M | $174.05M | (m) |
| 2015-03-31 | (m) | (m) | $3.73M | (m) | (m) | $128.50M | $159.13M | (m) |
| 2014-12-31 | (m) | (m) | $0.00 | $49.86M | (m) | $135.62M | $165.98M | (m) |
| 2014-09-30 | (m) | (m) | $10.07M | (m) | (m) | $134.46M | $164.63M | (m) |
| 2014-06-30 | (m) | (m) | $6.20M | (m) | (m) | $147.65M | $182.05M | (m) |
| 2014-03-31 | (m) | (m) | $2.40M | (m) | (m) | $164.49M | $197.69M | (m) |
| 2013-12-31 | (m) | (m) | $0.00 | $49.77M | (m) | $71.50M | $101.79M | (m) |
| 2013-09-30 | (m) | (m) | $5.97M | (m) | (m) | $65.31M | $110.15M | (m) |
| 2013-06-30 | (m) | (m) | $3.64M | (m) | (m) | $76.01M | $107.39M | (m) |
| 2013-03-31 | (m) | (m) | $1.36M | (m) | (m) | (m) | $116.87M | (m) |
| 2012-12-31 | (m) | (m) | $0.00 | $29.66M | (m) | (m) | $134.73M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |